JOIN DSMIG TODAY
This phase II study did not meet its primary and secondary endpoints on improvement in cognition and function
Roche statement: http://www.roche.com/media/store/statements.htm
LuMind statement1: https://www.lumindrds.org/response-on-the-roche-clinical-trial-for-clematis/
LuMind statement2: https://www.lumindrds.org/statement-from-lumind-research-down-syndrome-foundation-on-the-roche-clinical-trials/
DSMIG-USA is a 501(3)(c) Organization
Contact Us
Site Design by: Site to be Seen